scholarly journals The impact of pneumococcal conjugate vaccine on community-acquired pneumonia hospitalizations in children with comorbidity

2017 ◽  
Vol 176 (3) ◽  
pp. 337-342 ◽  
Author(s):  
Ellinor Sterky ◽  
Rutger Bennet ◽  
Ann Lindstrand ◽  
Margareta Eriksson ◽  
Anna Nilsson
Keyword(s):  
Conjugate Vaccine ◽  
Pneumococcal Conjugate Vaccine ◽  
Community Acquired Pneumonia ◽  
The Impact

scholarly journals Decrease of Pneumococcal Community-Acquired Pneumonia Hospitalization and Associated Complications in Children after the Implementation of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) in Taiwan

Vaccines ◽  
2021 ◽  
Vol 9 (9) ◽  
pp. 1043
Author(s):  
Ching-Fen Shen ◽  
Ju-Ling Chen ◽  
Chien-Chou Su ◽  
Wen-Liang Lin ◽  
Min-Ling Hsieh ◽  
...  
Keyword(s):  
Disease Severity ◽  
Conjugate Vaccine ◽  
Pneumococcal Conjugate Vaccine ◽  
Severe Pneumonia ◽  
Interrupted Time Series ◽  
Community Acquired Pneumonia ◽  
P Value ◽  
Implementation Program ◽  
Before And After ◽  
The Impact

The impact of the 13-valent pneumococcal conjugate vaccine (PCV13) on overall community-acquired pneumonia (CAP) and disease severity still needs thorough evaluation. In this study, we retrieve both pneumococcal CAP (P-CAP) and unspecific CAP (U-CAP) inpatient data from the Taiwan National Health Insurance Database (NHID) between 2005 and 2016. The interrupted time-series (ITS) analysis was performed to compare the incidence trend before and after the implementation of PCV13. After PCV13 implementation, there is a significant decreasing trend of P-CAP hospitalization, especially in children <1 year, 2–5 years, adults aged 19–65 years, 66 years, or older (all p value < 0.05). This corresponds to a 59% reduction in children <1 year, 47% in children aged 2–5 years, 39% in adult aged 19–65 years, and 41% in elderly aged 66 years or older. The intensive care rate (6.8% to 3.9%), severe pneumonia cases (21.7 to 14.5 episodes per 100,000 children–years), and the need for invasive procedures (4.3% to 2.0%) decreased in children aged 2–5 years (p value < 0.0001) with P-CAP. This PCV13 implementation program in Taiwan not only reduced the incidence of P-CAP, but also attenuated disease severity, especially in children aged 2–5 years.

The impact of heptavalent pneumococcal conjugate vaccine on the incidence of childhood community-acquired pneumonia and bacteriologically confirmed pneumococcal pneumonia in Japan

2015 ◽  
Vol 144 (3) ◽  
pp. 494-506 ◽  
Author(s):  
S. NAITO ◽  
J. TANAKA ◽  
K. NAGASHIMA ◽  
B. CHANG ◽  
H. HISHIKI ◽  
...  
Keyword(s):  
Conjugate Vaccine ◽  
Pneumococcal Conjugate Vaccine ◽  
Odds Ratio ◽  
Rate Ratio ◽  
Pneumococcal Pneumonia ◽  
Incidence Rate Ratio ◽  
Multidrug Resistant ◽  
Community Acquired Pneumonia ◽  
Heptavalent Pneumococcal Conjugate Vaccine ◽  
The Impact

SUMMARYHeptavalent pneumococcal conjugate vaccine (PCV7) was introduced to Japan in 2010. We investigated the impact of PCV7 on childhood community-acquired pneumonia (CAP) and pneumococcal pneumonia (PP). Children aged <5 years living in Chiba city, Japan, who were admitted to hospitals were enrolled to estimate the incidence of CAP based on the mid-year population. PP was determined by the presence of Streptococcus pneumoniae in cultured blood and/or sputum samples of CAP patients. The incidence of CAP and S. pneumoniae isolated from PP patients was compared before (April 2008–March 2009) and after (April 2012–March 2013) the introduction of PCV7 immunization. The annual incidence of CAP was reduced [incidence rate ratio 0·81, 95% confidence interval (CI) 0·73–0·90]. When comparing post-vaccine with pre-vaccine periods, the odds ratio for PP incidence was 0·60 (95% CI 0·39–0·93, P = 0·024). PCV7-covered serotypes markedly decreased (66·6% in pre-vaccine vs. 15·6% in post-vaccine, P < 0·01), and serotypes 6C, 15A, 15C and 19A increased. Multidrug-resistant international clones in the pre-vaccine period (Spain6B-2/ST90, Taiwan19F-14/ST236) decreased, while Sweden15A-25/ST63 was the dominant clone in the post-vaccine period. A significant reduction in the incidence of both CAP hospitalizations and culture-confirmed PP of vaccine serotypes was observed at 2 years after PCV7 vaccination.

scholarly journals Impact of the 7-valent pneumococcal conjugate vaccine on the incidence of childhood pneumonia

2012 ◽  
Vol 141 (8) ◽  
pp. 1697-1704 ◽  
Author(s):  
M. A. ELEMRAID ◽  
S. P. RUSHTON ◽  
M. D. F. SHIRLEY ◽  
M. F. THOMAS ◽  
D. A. SPENCER ◽  
...  
Keyword(s):  
Conjugate Vaccine ◽  
Pneumococcal Conjugate Vaccine ◽  
Community Acquired Pneumonia ◽  
Hospitalization Rate ◽  
Age Group ◽  
North East ◽  
Immunization Programme ◽  
Similar Survey ◽  
The Uk ◽  
The Impact

SUMMARYIn September 2006, the 7-valent pneumococcal conjugate vaccine (PCV7) was added to the UK immunization programme. We aimed to evaluate the impact of PCV7 on the incidence of all-cause community-acquired pneumonia (CAP) in children. A prospective survey was undertaken in 2008–2009 at 11 hospitals in North East England of children aged 0–16 years with radiologically confirmed pneumonia. Data were compared to those from a similar survey undertaken in the same hospitals in 2001–2002. A total of 542 children were enrolled, of which 74% were aged <5 years. PCV7 uptake was 90·7%. The incidence of pneumonia was 11·8/10 000 [95% confidence interval (CI) 10·9–12·9], and the hospitalization rate was 9·9/10 000 (95% CI 9·0–10·9). Compared to 2001, there was a 19% (95% CI 8–29) reduction in the rate of CAP in those aged <5 years, and in those <2 years a 33·1% (95% CI 20–45) reduction in the incidence of CAP and 38·1% (95% CI 24–50) reduction in hospitalization rates. However, for those unvaccinated aged ⩾5 years, there was no difference in the incidence of CAP and hospitalization rate between both surveys. Since 2001, the overall reduction in incidence was 17·7% (95% CI 8–26) and for hospitalization 18·5% (95% CI 8–28). For the <5 years age group there was a lower incidence of CAP in PCV7-vaccinated children (25·2/10 000, 95% CI 22·6–28·2) than in those that were not vaccinated (37·4/10 000, 95% CI 29·2–47·1). In conclusion, PCV7 has reduced both incidence and rate of hospitalization of pneumonia in children, particularly in the <2 years age group.

Sign in / Sign up

Export Citation Format

Share Document